Restoration of Normal Hemoglogbin Level in Patients with Sever Chronic Congestive Heart Failure Accompanied by Anemia
WANG Jun,ZHANG Yan,ZHOU Yun,HUANG Shao-hua,TAO Wen-qi,XU Zhi-qiang,CAO Bin,TANG Qi,FANG Wei-yi
DOI: https://doi.org/10.3969/j.issn.1673-6583.2012.01.017
2012-01-01
Abstract:Objective:To evaluate the clinical safety and efficacy of treating severe chronic congestive heart failure accompanied by anemia using low-dose recombinant human erythropoietin(rhEPO) plus iron.Methods:A total of 128 patients with chronic heart failure(NYHA functional class Ⅲ and above),left ventricular ejection fraction less than 0.4,and hemoglobin level below 100g/L were selected and randomly divided into the anemia treatment group(n=66) and the control group(n=62).A 12-month follow-up observational study was conducted to record event-free survival,primary endpoint events(hospitalization due to worsening heart failures,deaths from heart failures),and secondary endpoint events(deaths from causes other than heart failure,sudden deaths,myocardial infarctions,unstable anginas,strokes,arterial embolisms,and discontinuations due to adverse drug reactions).Left ventricular ejection fraction(LVEF),wall stress(MWS),mass index(LVMI),TNF-α,hsCRP,and BNP levels before and after the treatment were compared between the two groups.Results:Compared with the control group,the treatment group had longer event-free survival time,but showed no significant differences in heart failure-induced death and hospitalization rates.Also,no increase in cardiovascular events was observed in the treatment group.MWS and LVMI values decreased significantly after the treatment in the treatment group,in striking contrast with the control group.However,no differences were seen between the two groups in the LVEF,BNP,TNFa,and hsCRP levels.Conclusion:Patients with severe chronic congestive heart failure accompanied by anemia can be safely treated using low-dose rhEPO plus iron.Preliminary studies show that this approach can elongate survival time and improve left ventricular functions,but does not necessarily lower heart failure-induced death and hospitalization rates.